Table 4.
Clinical outcome versus alpha-lysin production among patients with Staphylococcus aureus hospital-acquired pneumoniab
| S. aureus type and amt of alpha-lysina | PVL+ |
PVL− |
||||
|---|---|---|---|---|---|---|
| No. of isolates |
No. of isolates |
|||||
| Cure | Failure | Total | Cure | Failure | Total | |
| MRSA | ||||||
| High | 4 (80.0) | 1 (20.0) | 5 | 1 (100.0) | 0 | 1 |
| Low | 12 (92.3) | 1 (7.7) | 13 | 13 (76.5) | 4 (23.5) | 17 |
| Total | 16 (88.9) | 2 (11.1) | 18 | 14 (77.8) | 4 (22.2) | 18 |
| MSSA | ||||||
| High | 2 (100.0) | 0 | 2 | 1 (50.0) | 1 (50.0) | 2 |
| Low | 1 (33.3) | 2 (66.7) | 3 | 1 (33.3) | 2 (66.7) | 3 |
| Total | 3 (60.0) | 2 (40.0) | 5 | 2 (40.0) | 3 (60.0) | 5 |
a
High, >10 HU/ml; low, ≤10 HU/ml.
b
The P value for MRSA and MSSA pooled was 1.00, as calculated by using an exact Monte Carlo Cochran-Mantel-Haenszel test, with stratification on methicillin susceptibility (MRSA or MSSA).